Efficacy observation of wound care ointment (suile) on incision healing after mixed hemorrhoid surgery Authors: Baozhen He, Qinghua Bai, Eslam Ghaleb, Xiaoli Wu, Weifeng Mao, Wu Zhang Published: 2026 ABSTRACT AbstractBackgroundPostoperative complications, including severe pain, perianal edema, and prolonged wound healing, significantly impact patient recovery following mixed hemorrhoid surgery. This study aimed to evaluate the clinical efficacy of a topical wound care ointment (Suile) in promoting postoperative recovery and tissue remodeling.MethodsIn this randomized controlled trial, 78 patients with stage III–IV mixed hemorrhoids were enrolled and allocated to either a treatment group (topical Suile ointment containing bismuth subgallate and borneol) or a control group (standard povidone-iodine care). Primary and secondary outcomes included pain intensity (Visual Analog Scale, VAS), wound edema scores, scar formation (Vancouver Scar Scale, VSS), and clinical cure rate. Data were analyzed using repeated-measures ANOVA with Bonferroni post-hoc corrections to assess longitudinal recovery patterns.ResultsBy day 28, the treatment group demonstrated a significantly higher clinical cure rate compared to the control group (69.23% vs. 35.90%, P < 0.01). Repeated-measures ANOVA revealed highly significant improvements in the treatment group for both pain and scar formation. Specifically, VAS scores were significantly lower in the Suile group from days 3 to 14 (P < 0.001), with a large effect size at the primary endpoint (day 7, Cohen’s d = 0.88). Furthermore, Suile application led to significantly superior scar outcomes (VSS scores) by the end of the follow-up period (Group effect P < 0.001; day 28 P < 0.001). While wound edema scores were lower in the treatment group at several time points, the overall group effect for edema did not reach statistical significance (P = 0.146). No serious adverse events were reported.ConclusionTopical application of Suile ointment significantly alleviates postoperative pain, enhances the quality of scar formation, and accelerates overall wound healing after mixed hemorrhoid surgery. These findings suggest that Suile is a safe and effective therapeutic option for optimizing postoperative recovery in proctological practice.Trial registrationChinese Clinical Trial Registry (ChiCTR), ChiCTR2600123181. Registered on 22 April 2026. Retrospectively registered.The trial was registered retrospectively due to administrative delays; however, the study protocol and outcomes were defined prior to patient enrollment.”Keywords: Mixed hemorrhoids, Wound care ointment (suile), Incision healing, Efficacy Introduction Hemorrhoids are soft venous growths caused by dilatation and varicosity of the venous plexus beneath the rectal mucosa and the skin of the anal canal. They are one of the most prevalent anorectal diseases, and their prevalence worldwide ranges from 4% to 55% [1, 2]. By means of epidemiological comparison, it has been found that Kazakhstan has the lowest rate of disease, and China has the highest rate of prevalence [3, 4]. In China, a recent investigation has shown that anorectal diseases have a prevalence of up to 51.14% among those aged more than 18 years, and he overall prevalence of hemorrhoids reached 50.28%.. Mixed hemorrhoids occur in about 22.00% of hemorrhoid cases [5]. Stage III-IV hemorrhoids are treated by conventional surgery [6]. To avoid postoperative edema, a "V" incision is normally performed at the 6 o'clock position in surgery, lowering the tension of the anal canal and allowing for balanced decompression [7]. Owing to the characteristics of the anus anatomy, postoperative complications like wound edema, bleeding, pain [8], and delayed healing are common. In addition, parameters like bacterial accumulation and intraoperative tissue injury increase complications like infection, pain, bleeding, scar formation, and slow recovery. Hence, efficient methods involving the relief of pain, minimization of scar formation and edema, and enhanced wound healing are required for facilitating early social readjustment [9–11]. Suile, a new wound ointment made mainly of Bismuth Subgallate and Borneol, has demonstrated promising clinical efficacy. Earlier research [11] shows that it accelerates wound healing, suppresses bleeding, relieves pain, suppresses bacterial growth, suppresses inflammation, and decreases scar formation. It is often employed for treating a variety of surgical wounds. This study aimed to evaluate the therapeutic effect of Suile as a perianal wound dressing for mixed hemorrhoid surgery and its influence on incision recovery and postoperative recovery. Methods Study design The study was a single-center, randomized controlled trial that included 100 patients with mixed hemorrhoid disease who underwent surgical intervention in the Department of Anorectal Surgery of Pengzhou People's Hospital from May 2023 through April 2024. Ethical clearance for the study was provided by the Pengzhou People's Hospital Ethics Committee (Approval No.: 2022-005). The study complied with the ethical standards described in the Declaration of Helsinki. All the participants were fully informed of the purpose of the study and provided voluntary participation. Written informed consent that included the study purpose, procedures, and participants' right to withdrawal at will was received from each participant prior to data collection. The study was conducted and reported in accordance with the CONSORT guidelines. Inclusion criteria Patients were recruited in the study if they met the following criteria: Diagnosis of Grade III/IV hemorrhoids according to the Goligher classification. Diagnosis of Grade III/IV hemorrhoids according to the Goligher classification. Age > 18 years, either sex. Age > 18 years, either sex. No underlying conditions that could affect wound healing (e.g., diabetes mellitus). No underlying conditions that could affect wound healing (e.g., diabetes mellitus). No history of anal surgery or anorectal stenosis, with normal anal appearance, sensation, and continence function. No history of anal surgery or anorectal stenosis, with normal anal appearance, sensation, and continence function. • Voluntary entry and provided a complete and accurate medical history, capacity to tolerate adherence with follow-up testing, and signed informed consent. Exclusion criteria Patients were excluded from participation if they met any of the following criteria: Presence of concurrent perianal diseases, such as anal fissures, fistulas, perianal abscesses, inflammatory bowel disease, or colorectal polyps. Presence of concurrent perianal diseases, such as anal fissures, fistulas, perianal abscesses, inflammatory bowel disease, or colorectal polyps. History of keloid formation, multiple drug allergies, or substance abuse. History of keloid formation, multiple drug allergies, or substance abuse. Severe systemic diseases, uncontrolled infections, or intolerance to surgery. Severe systemic diseases, uncontrolled infections, or intolerance to surgery. Menstruating or lactating women, or pregnant women. Menstruating or lactating women, or pregnant women. Presence of scar tissue at the anal verge or any abnormal anal function. Presence of scar tissue at the anal verge or any abnormal anal function. Chronic intractable constipation or diarrhea, or coagulopathy. Chronic intractable constipation or diarrhea, or coagulopathy. Concurrent participation in other clinical trials. Concurrent participation in other clinical trials. Case withdrawal criteria The participants were excluded from the study under the following situations: Loss of follow-up or incomplete data that could affect efficacy or safety comparisons. Loss of follow-up or incomplete data that could affect efficacy or safety comparisons. Intraoperative complications that prevented the completion of surgery or required alternative treatments. Intraoperative complications that prevented the completion of surgery or required alternative treatments. Study procedure Admitted patients were screened for eligibility by the operating surgeon. Eligible patients were informed about the study by nursing staff and invited to participate voluntarily. All patients with grade III–IV mixed hemorrhoids underwent hemorrhoidectomy using external dissection and internal ligation combined with a “V”-shaped decompression incision at the 6 o’clock position of the anal canal, a standard surgical technique at our institution. Briefly, under sacral anesthesia, patients were placed in the lithotomy position. After routine disinfection and adequate anal dilation, the hemorrhoidal tissue was exposed. A fusiform incision was made along the hemorrhoidal margin, and the external hemorrhoidal venous plexus was dissected up to the dentate line. The base of the internal hemorrhoid was ligated with absorbable sutures, followed by excision of the hemorrhoidal tissue. A “V”-shaped decompression incision (approximately 1.5–2.0 cm) was then created at the 6 o’clock position of the anal canal to reduce anal canal tension. After meticulous hemostasis, the wound was packed with Vaseline gauze and covered with sterile dressing. All procedures were performed by experienced colorectal surgeons following standardized institutional protocols. The eligible patients were randomly allocated to either the treatment group or the control group using a random number table generated by admissions staff who were not involved in patient recruitment, treatment, or outcome assessment. Allocation concealment was ensured using sequentially numbered, opaque, sealed envelopes containing the group assignments. Upon enrollment, the study staff opened the next envelope in sequence to assign the participant to the corresponding group. The treatment group received topical application of Suile wound care ointment. The formulation consists of bismuth subgallate (4.5%) and borneol (0.7%) in a petrolatum base (94.8%). The ointment was supplied in 10 g tubes and applied to the surgical wound according to standardized postoperative care protocols. Dressing changes were performed uniformly by a designated clinician throughout the study period. Due to the nature of the intervention, blinding of patients and treating clinicians was not feasible. However, to minimize observer bias for subjective outcomes, data collection was conducted independently by two trained evaluators who were blinded to group allocation. A third blinded investigator calculated the final values as the average of the two independent assessments. The sample size was calculated using the power analysis method. Based on the study design (randomized controlled trial) and the primary outcome indicator, core parameters were set with reference to previous studies on postoperative care of mixed hemorrhoids: significance level α=0.05, statistical power 1−β=0.80, and a dropout rate of 15% was considered. Through calculation using the power formula, the minimum sample size for a single group was determined to be 16 cases, with a total of 32 cases in the two groups. During the actual conduct of the study, 100 patients were initially assessed for eligibility. After screening for eligibility, 11 were ineligible, 8 met the exclusion criteria, and 3 refused to take part, leaving 78 patients enrolled in the study. According to the 1:1 grouping principle, there were 39 patients in both the experimental group (Suile Wound Care Ointment group) and the control group. (39 in each of the groups represented in Fig. 1). Flowchart of patient enrollment in the study Postoperative care and interventions In the control group, the perianal incisions were disinfected with povidone-iodine, and then a sterile gauze dressing with breathable adhesive tape was applied over them and secured with the tape. These dressings were changed every day. Perianal incisions in the treatment group were similarly disinfected with povidone-iodine, followed by the application of a Suile ointment at a rate of about 1 mm applied uniformly. The gauze dressings with the breathable tape over the incision were then secured and changed every day. Data collection and outcome measures The primary endpoint of this study was postoperative pain intensity measured by the Visual Analog Scale (VAS) on postoperative day 7. Secondary outcomes included wound edema scores, scar formation assessed by the Vancouver Scar Scale (VSS), and overall clinical cure rate. Demographic and clinical baseline data were retrieved from the hospital database. Postoperative outcomes—including pain intensity, edema, infection, and scar hyperplasia—were evaluated on postoperative days 1, 3, 5, 7, 14, 21, and 28. Incision healing time and overall clinical efficacy were also recorded. Pain was assessed using the Visual Analog Scale (VAS) [12], while scar formation was evaluated with the Vancouver Scar Scale (VSS) [13]. Anal verge edema and wound healing were scored according to the Criteria for Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine. The edema scoring system was defined as follows: 0 = no edema; 1 = edema area ≤ 0.5 cm; 2 = edema area 0.5–1.0 cm; 3 = edema area 1.0–2.0 cm; and 4 = edema area ≥ 2.0 cm. Wound healing was categorized as: (1) Cure—wound completely filled with granulation tissue and covered by regenerated epithelium; (2) Markedly Effective—wound largely filled with granulation tissue, area reduced by >75%; (3) Effective—fresh granulation tissue present, area reduced by 25–75%; and (4) Ineffective—wound area reduction <25%. For clarity and consistency with international reporting standards, the “cure rate” was defined as the proportion of patients achieving complete wound healing (“Cure”). The wound healing and edema assessment criteria were based on standardized Traditional Chinese Medicine (TCM) guidelines commonly used in clinical practice in China for evaluating postoperative anorectal outcomes. These criteria have been applied in previous clinical studies and reflect routine clinical assessment in the study setting. Although they are not widely adopted internationally, they provide practical value for evaluating wound recovery in this population. This limitation is acknowledged and discussed. Statistical analysis All statistical analyses were performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables with normal distribution were expressed as mean ± standard deviation (SD) and compared using the independent-samples t-test. Non-normally distributed data were presented as median (interquartile range) and analyzed using the Mann–Whitney U test. Categorical variables were expressed as frequencies and percentages and compared using the χ2 test. For repeated measurements (postoperative pain, edema, and scar scores), repeated-measures analysis of variance (RM-ANOVA) was performed to evaluate the effects of time, group, and time × group interaction. Bonferroni correction was applied for multiple comparisons. Effect sizes were reported using partial eta squared (ηp2) for RM-ANOVA and Cohen’s d for pairwise comparisons. Mean differences (MD) with 95% confidence intervals (95% CI) were also calculated. A two-tailed P value < 0.05 was considered statistically significant. The sample size was reasonably calculated in advance using power analysis. According to previous studies on mixed hemorrhoid surgery, the parameters were set as α=0.05, 1−β=0.80, with an anticipated 15% dropout rate. The minimum required sample size was calculated, and a total of 78 eligible patients were finally enrolled and equally divided into two groups, ensuring sufficient sample representativeness and statistical validity. Results Demographic and Clinical Characteristics The demographic and clinical characteristics at baseline were comparable between the two groups, with no statistically significant differences observed (all P > 0.05) (Table 1). This ensures that the baseline profile of patients in both the Suile and control groups was well-balanced. Table 1Demographic characteristics of the participantsControl groupTreatment groupN%N%GenderMale1641.03%1538.46%P>0.05Female2358.97%2461.54%Marital statusMarried3487.18%3282.05%P>0.05Unmarried512.82%615.38%Divorced00%12.56%Education levelIlliterate25.13%00.00%P>0.05Primary school615.38%717.95%Junior high school1538.46%1333.33%High school37.69%512.82%University1333.33%1435.90%Age44.77±13.7242.10±14.34P>0.05BMI23.79±3.6623.69±3.96P>0.05 Demographic characteristics of the participants Postoperative Pain (VAS Scores) Postoperative pain, assessed using the Visual Analog Scale (VAS), showed a significant improvement in the treatment group. While no significant differences were observed on days 1, 21, and 28 (P > 0.05), the Suile group recorded significantly lower pain scores on days 3, 5, 7, and 14 (all P < 0.001). Repeated-measures ANOVA confirmed a significant group effect [F (1, 76) = 19.42, P < 0.001] and a significant time × group interaction [P < 0.001]. Notably, at the predefined primary endpoint (postoperative day 7), the treatment demonstrated a large effect size (Cohen’s d = 0.88), indicating a clinically meaningful reduction in pain intensity (Figure 2, Table 2). Comparison of postoperative pain scores (VAS). Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using repeated-measures ANOVA followed by Bonferroni-adjusted post hoc comparisons. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001 Table 2Results of repeated-measures ANOVA and pairwise comparisons for postoperative pain (VAS), wound edema, and scar formation (VSS) scoresOutcomeEffectStatisticP-valueEffect SizeMean Difference (95% CI)InterpretationPain (VAS)Time effectF (6,456) =289.37<0.001ηp2 ​=0.79–SignificantGroup effectF (1,76) =19.42<0.001ηp2 ​=0.20–SignificantTime × GroupF (6,456) =5.83<0.001ηp2 ​=0.07–SignificantDay 7 comparisont=3.82<0.001d=0.880.75(0.29–1.21)SignificantEdemaTime effectF (6,456) =42.69<0.001ηp2 =0.36–SignificantGroup effectF (1,76) =2.150.146ηp2​ =0.03–Not significantTime × GroupF (6,456) =1.890.082ηp2​ =0.02–Not significantDay 7 comparisont=1.210.230d=0.270.15(−0.10–0.40)Not significantScar (VSS)Time effectF (6,456) =67.82<0.001ηp2​ =0.47–SignificantGroup effectF (1,76) =31.58<0.001ηp2​ =0.29–SignificantTime × GroupF (6,456) =4.270.001ηp2​ =0.05–SignificantDay 28 comparisont=4.36<0.001d =1.011.23(0.57–1.89)Significant Results of repeated-measures ANOVA and pairwise comparisons for postoperative pain (VAS), wound edema, and scar formation (VSS) scores Wound Edema Wound edema scores were lower in the treatment group at several postoperative time points. However, repeated-measures ANOVA did not demonstrate a statistically significant overall group effect [F(1, 76) = 2.15, P = 0.146] or a significant time × group interaction [P = 0.082] (Table 2). This suggests that while there was a downward trend in edema for the Suile group, the difference did not reach global statistical significance compared to the control group (Figure 3). Comparison of postoperative edema scores. Data are presented as mean ± standard deviation (SD). Statistical analysis was performed using repeated-measures ANOVA followed by Bonferroni-adjusted post hoc comparisons. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001 Scar Assessment (Vancouver Scar Scale) In contrast to the preliminary findings, the final repeated-measures ANOVA for the Vancouver Scar Scale (VSS) scores revealed a highly significant group effect [F (1, 76) = 31.58, P < 0.001] and a significant time × group interaction [P = 0.001]. Post-hoc comparisons showed that the treatment group achieved significantly better scar quality compared to the control group. Specifically, the difference was most pronounced at day 28 (P < 0.001), with a very large effect size (Cohen’s d = 1.01), indicating that Suile ointment significantly enhances long-term tissue remodeling and scar outcomes (Figure 4, Table 2). Comparison of Vancouver Scar Scale (VSS) scores. Data are presented as mean ± SD. Statistical analysis was performed using repeated-measures ANOVA with Bonferroni-adjusted post hoc comparisons. ns, not significant *P < 0.05 **P < 0.01,***P < 0.001 Clinical Efficacy and Healing Rates. The overall clinical cure rate was significantly higher in the treatment group. By day 28, 69.23% (27/39) of patients in the Suile group achieved complete wound healing, compared to only 35.90% (14/39) in the control group (P < 0.01) (Table 3). This represents a substantial clinical benefit in accelerating the recovery process. Table 3Evaluation of therapeutic effects at Days 21 and 28Day 21Day 28Control groupTreatment groupControl groupTreatment groupInvalid0000Effective14130Markedly Effective25312212Cured071427Cure rate017.95%35.90%69.23%P <0.05P <0.01 Evaluation of therapeutic effects at Days 21 and 28 Safety Profile Adverse events were actively monitored at each follow-up visit through clinical examination and patient self-report. No serious adverse events were observed in either group. No missing data were observed during follow-up. Specifically, no cases of local allergic reactions, secondary wound infections, or anal stenosis related to the use of Suile ointment were reported during the 28-day follow-up period, confirming the safety and tolerability of the treatment for postoperative wound care. Discussion The present randomized controlled trial demonstrates that the topical application of Suile ointment significantly improves clinical outcomes following mixed hemorrhoid surgery. The most notable findings include a substantial reduction in postoperative pain and a significant enhancement in scar quality (VSS scores), alongside a higher overall clinical cure rate compared to the control group. Suile is a topical wound care formulation primarily composed of bismuth subgallate and borneol. Bismuth subgallate is well-recognized for its hemostatic and anti-inflammatory properties. Beyond local coagulation, experimental evidence suggests that it modulates wound healing by inhibiting the synthesis of nitric oxide (NO) and prostaglandin E2 (PGE2), while potentially regulating transforming growth factor-β1 (TGF-β1) expression [14]. These molecular pathways are crucial for promoting granulation tissue formation and accelerating epithelial migration. Additionally, its antimicrobial activity against common pathogens like Staphylococcus aureus [15, 16] provides a protective environment for the surgical site. While these mechanisms are primarily derived from experimental models, our clinical findings regarding accelerated healing rates (69.23% vs 35.90%) provide robust clinical correlation. Postoperative pain is a major hurdle in proctological surgery, often driven by tissue trauma, nerve exposure, and localized inflammation [17, 18]. While systemic NSAIDs are standard practice, they are frequently insufficient and carry systemic risks [19, 20]. In our study, the Suile group showed significantly lower VAS scores at critical early time points (Days 3–14). Most importantly, at the primary endpoint (Day 7), the treatment exhibited a large effect size (Cohen’s d = 0.88). This suggests that Suile provides a potent local analgesic effect, likely by creating a protective barrier over exposed nerve endings and modulating the local inflammatory milieu, thereby reducing the "peripheral sensitization" common after hemorrhoidectomy [21]. Postoperative edema results from vascular disruption and acute inflammatory exudation [22, 23]. While we observed lower edema scores in the Suile group at several intervals, the repeated-measures ANOVA did not reach global statistical significance (P = 0.146). This indicates that while Suile may offer some degree of symptomatic relief for swelling, its anti-edematous effect is more modest compared to its analgesic and pro-healing properties. This finding emphasizes that Suile’s primary strength lies in pain management and tissue remodeling rather than acute fluid volume reduction. A key finding of this study is the significant improvement in scar quality, as evidenced by the Vancouver Scar Scale (VSS) scores at Day 28. In contrast to many previous studies where long-term scar differences were negligible, our data revealed a highly significant group effect (P < 0.001) and a large effect size (Cohen’s d = 1.01). Excessive fibrosis after hemorrhoid surgery is a risk factor for anal stenosis and functional impairment [24]. Sulile, by delaying premature wound contraction and promoting epithelialization, improved scar outcomes in our study. On day 28, the test group demonstrated significantly lower Vancouver Scar Scale (VSS) scores, confirming its role in improving scar quality and accelerating functional recovery. Several limitations warrant consideration. First, the use of assessment criteria based on Traditional Chinese Medicine (TCM) may limit the international generalizability of some secondary outcomes. Second, being a single-center study with a 28-day follow-up, the long-term definitive prevention of anal stenosis requires further longitudinal data. Future research should utilize internationally standardized wound scoring systems and multi-center designs to validate these findings across broader populations. Conclusion In conclusion, Suile ointment provides a clinically meaningful benefit in reducing postoperative pain and significantly improving scar quality after mixed hemorrhoid surgery. Given its excellent safety profile and high patient tolerability, it represents a valuable therapeutic option for enhancing recovery in proctological wound care. Strengths and limitations Strengths This study found that Suile ointment applied to perianal wounds after mixed hemorrhoid surgery effectively reduces postoperative pain and improves the quality of scar formation. While the reduction in edema did not reach global statistical significance, a downward trend was observed. Overall, the treatment significantly promotes wound healing and increases the clinical cure rate by day 28, thereby improving the postoperative recovery experience for patients. Limitations This study has several limitations. First, it was conducted at a single center with a relatively small sample size, which may limit the generalizability of the findings. Second, although randomization was implemented, blinding of patients and treating clinicians was not feasible, which may introduce performance and detection bias, particularly for subjective outcomes such as pain and edema. Third, the use of TCM-based assessment criteria may limit comparability with international studies. Finally, although a post hoc power analysis suggested adequate power for the primary outcome, the sample size may be insufficient for detecting differences in some secondary outcomes. Acknowledgments The authors thank all patients who participated in this study and all researchers for their contributions to this manuscript. Authors’ contributions Author Contributions​​ B.H conceived the project and drafted the manuscript; Q.B ensured the implementation of the project and provided supervision;E.G wrote part of the manuscript and performed English proofreading; X.W collected the experimental data; W.Z analyzed part of the data and conducted preliminary literature collection; W.M proofread the article.All authors have read and approved the final manuscript.​ Funding This article is supported by the Special Scientific Research Project on Wound Diseases (Taige) of the Sichuan Medical Association in 2022 (2022TG18). Data availability The Ungdata surveys that support the findings of this study are available from PengZhou People's Hospital, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. The data are, however, available upon request and with the permission of PengZhou People's Hospital. Declarations Ethics approval and consent to participate The study protocol was approved by the Ethics Committee of Pengzhou People's Hospital (Approval No.: 2022-005). The study was conducted in accordance with the principles of the Declaration of Helsinki. All treatments followed standard protocols, and all patients provided written informed consent. Consent for publication Not Applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The Ungdata surveys that support the findings of this study are available from PengZhou People's Hospital, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. The data are, however, available upon request and with the permission of PengZhou People's Hospital.